Prostate imaging drug Pylarify has become the first radiodiagnostic blockbuster, achieving over $1 billion in sales for 2024. The addressable market continues to expand.

Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024Free cash flow was $141.4 million and $493.1 ...

Q4 2024 Earnings Call Transcript February 26, 2025 Operator: Good morning. Welcome to the Lantheus Fourth Quarter and Full ...

Lantheus Holdings, Inc. (NASDAQ:LNTH) announced its second acquisition this month; this time for private company Evergreen Theragnostics for $250 million in cash plus milestones valued at $752.5 ...

Lantheus, a Massachusetts-based developer of radiopharmaceuticals, has agreed to acquire the radiopharma contract development and manufacturing organization (CDMO) Evergreen Theragnostics.

Welcome to the Lantheus fourth quarter and full year 2024 conference call. (Operator Instructions) This call is being recorded, and a replay will be available in the Investors section of the company's ...

Roanna Ruiz’s rating is based on the strategic acquisition of Evergreen Theragnostics by Lantheus, which is seen as a significant step in enhancing its radiopharmaceutical infrastructure.

In the fourth quarter of 2024, the US Gross Domestic Product (GDP) expanded at an annual rate of 2.3%, slightly below market ...

Lantheus Holdings Inc (($LNTH)) has held its Q4 earnings call. Read on for the main highlights of the call. Lantheus Holdings Inc. recently held ...

We recently published a list of 15 Best Fast Growth Stocks To Buy Right Now. In this article, we are going to take a look at ...

Well before market open that morning, Lantheus announced that it has signed a definitive agreement to acquire clinical-stage peer Evergreen Theragnostics. For its new asset, Lantheus will make an ...